newsfilter
← Latest News
Business Wire·

LYNKUET® (elinzanetant) Receives Expanded Market Authorization in Canada for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy (AET) Related to Breast Cancer

Expanded authorization introduces a treatment option for women experiencing moderate to severe hot flashes and/or night sweats caused by adjuvant endocrine therapy (AET) related to breast cancer LYNKUET® is the